Trials / Completed
CompletedNCT05808049
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health
A Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Vedic Lifesciences Pvt. Ltd. · Industry
- Sex
- All
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | MXP22 (Probiotic and antioxidant capsule) | Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days |
| OTHER | Placebo (Microcrystalline Cellulose) | Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days |
Timeline
- Start date
- 2022-10-06
- Primary completion
- 2023-07-04
- Completion
- 2023-07-04
- First posted
- 2023-04-11
- Last updated
- 2023-09-06
Locations
2 sites across 1 country: India
Source: ClinicalTrials.gov record NCT05808049. Inclusion in this directory is not an endorsement.